Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo - Healthy Participants Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers

NCT01550458
View directory record Official record
Conditions
Healthy
Interventions
mibefradil, Placebo
Drug · Other
Lead sponsor
Cavion, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

NCT05536440
View directory record Official record
Conditions
Healthy
Interventions
PF-07261271, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

NCT00971802
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-03882845 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602
View directory record Official record
Conditions
Venous Thrombosis
Interventions
MK-2060, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

NCT05760937
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986447, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

NCT02148744
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions
XmAb7195, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

NCT02353299
View directory record Official record
Conditions
Healthy
Interventions
Silenor 6 mg, zolpidem 10 mg, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of LY3985297 in Healthy Participants

NCT06395012
View directory record Official record
Conditions
Healthy
Interventions
LY3985297, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 6, 2026, 6:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511
View directory record Official record
Conditions
Pandemic Influenza Immunization, Healthy Volunteers
Interventions
Pandemic flu H5 HA mRNA SD2 vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
13
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

NCT02625636
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR438544, placebo, r-glucagon
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

NCT02889367
View directory record Official record
Conditions
Healthy
Interventions
Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 6, 2026, 6:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

NCT05428228
View directory record Official record
Conditions
Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Cognitive Performance
Interventions
TP1, TP2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Metformin in Longevity Study (MILES).

NCT02432287
View directory record Official record
Conditions
Aging
Interventions
Metformin, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
voclosporin ophthalmic solution
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 6, 2026, 6:16 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

NCT04620109
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
KDR2-2, Placebo
Drug
Lead sponsor
Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 6, 2026, 6:16 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 6, 2026, 6:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense

NCT03700892
View directory record Official record
Conditions
Smoking, Healthy
Interventions
Cinnamaldehyde e-liquid, PG/VG e-liquid
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine/Chloroquine DDI Study

NCT00871156
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine, Tafenoquine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

NCT01136356
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of LY3041658 in Healthy Participants

NCT02148627
View directory record Official record
Conditions
Healthy
Interventions
LY3041658 (SC), LY3041658 (IV), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 6, 2026, 6:16 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effects of Hesperidin on Insulin Sensitivity

NCT01773486
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Hesperidin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

NCT06511973
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline, A solution of 0.2% SLS
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

NCT01809353
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54452840, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 6, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 6:16 AM EDT